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 There is an epidemic of chronic kidney disease of unknown origin (CKDu) 
primarily affecting younger men in Central America, especially El Salvador and 
Nicaragua. The primary hypothesis has included heat stress and dehydration. Although 
medication usage is widely viewed as a likely contributor to kidney damage, the 
association with chronic kidney disease in Central America has not been fully explored. 
This study investigated medication usage, symptom presentation, and kidney function  
among 524 outdoor workers in agricultural and non-agricultural industries enrolled in the 
Mesoamerican Nephropathy Occupational Study (MANOS) led by Boston University 
researchers. An overview of the literature on the adverse effects of medication on renal 
function and thermoregulation, with a focus on medications considered in MANOS, was 
conducted. Medication usage and symptom presentation on both a short- and long-term 
timeframe were explored in relation to kidney function measured by estimated 
glomerular filtration rate. Long-term usage of NSAIDS and potassium supplements was 
significantly associated with kidney function. Neither short- or long-term uses of 
acetaminophen, the most commonly used medication, were associated with kidney 
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function. While several self-reported health symptoms were significantly associated with 
lower kidney function in crude models, the associations’ significance levels lessened after 
adjusting for age, country, and industry. In contrast, symptoms of chistata (a local term 
for painful urination) and lower abdominal pain three months prior to data collection each 
significantly predicted higher kidney function. The results of this exploratory, cross-
sectional study present an opportunity for further study on how medications and 
symptoms, related to both nephrotoxicity and heat stress, could be associated with kidney 
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Chronic kidney disease (CKD) is a huge and increasing global health burden.1 It 
is marked by gradual decline and loss of kidney function over time and has potentially 
severe health consequences.2 This differs from acute kidney injury (AKI), or acute renal 
failure, which is defined by a sudden event that presents with clinically apparent damage 
or failure of the kidney over a period of hours or days.3 
The 2010 Global Burden of Disease study stated that CKD rose from the 17th 
leading cause of death in 1990 to the 12th in 2017.1 In 2017, an estimated 1.2 million 
people died from chronic kidney disease; global mortality rates across all ages were 
estimated to have increased by 41.5% from 1990 to 2017, although age standardized rates 
were stable and did not significantly increase.1,4 As far as we can tell, disease prevalence 
has also increased worldwide, although there is no registry or standard documentation of 
diagnoses. 
Traditionally, the majority of chronic kidney disease cases can be attributed to 
diabetes (type 1 and 2) or hypertension.1 There is also a positive association with age. 
From 1990 to 2017, the correlation between age and chronic kidney disease has increased 
in the global population, where currently the vast majority of cases occur in the elderly.1 
However, there are several CKD “hotspots” around the world with varying clinical 
presentations and unknown causes.5 Along the Pacific coast of Central America, in El 
Salvador and Nicaragua, a hotspot of Chronic Kidney Disease of unknown etiology 
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(CKDu) has been studied by the Boston University Research Group for the Study of 
Chronic Kidney Disease in Central America for 10 years.6 
CKDu in El Salvador and Nicaragua 
 Nicaragua and El Salvador are especially affected by CKDu. One estimate 
indicates that from 1997-2012, mortality rates increased from 23.9 to 36.7 per 100,000 in 
El Salvador and 18.7 to 47.4 per 100,000 in Nicaragua.7 Bikbov et al. estimated age 
standardized prevalence rates in Central America to be 11,116 per 100,000, with 
approximated death rates of 42.1 per 100,000.1 Although Bikbov et al. estimated that age 
standardized prevalence in these two countries matched closely with the Central 
American average, they claimed that death rates were higher than the Central American 
estimate of 42.1/100,000, with El Salvador at approximately 71.4/100,000 and Nicaragua 
at approximately 49.4/100,000.1 
Specific demographics in Nicaragua and El Salvador provide further evidence for 
the high burden of disease relative to other countries alongside nontraditional risk factors. 
Ordunez et al. showed that the premature mortality rates of Nicaragua and El Salvador 
greatly exceeded those of the US and Cuba across all age groups and gender; Nicaragua 
and El Salvador had between 9-fold and 12-fold higher mortality rates.7 Mortality was 
also more frequent in men than in women.7 A prevalence study in Nicaragua’s 
Quezalguaque region in 2010 found an overall prevalence of 12.7% with the disease 




Also known as Mesoamerican Nephropathy (MeN), CKDu in Central America 
clinically resembles chronic tubulointerstitial nephritis. It is not preceded by diabetes or 
hypertension and particularly affects agricultural communities.9,10 It also 
disproportionality affects younger individuals relative to traditional CKD, especially 
young men under age 45.7 These demographics and lack of risk factors do not fit into 
traditional chronic kidney disease etiology.  
CKDu appears to be a multifactorial disease. Hypotheses include climate, 
pesticide and heavy metal exposure, medication usage, and socioeconomic status. 
However, a large focus of CKDu risk factor research in Central America is the role of 
occupational heat stress and resulting dehydration. Backed by several animal and 
epidemiological studies, researchers have hypothesized that constant heat stress, whether 
from climate, occupation, or both, contributes to dehydration, which when repeated over 
time can lower blood flow through the kidneys (volume depletion) and prime them for 
damage and disease. Animal models have shown that repeated heat exposure can elevate 
biomarkers of kidney injury, drawing a comparison to human kidney injury under 
repetitive heat exposure.11,12 Several reviews and cohort studies have also found 
epidemiological associations between occupational heat stress and lowered glomerular 
filtration rates (GFR), while several also considered the connecting factor of dehydration 
from work in the heat.13–20 Although the official definition of CKD requires lowered GFR 
measurements separated by a period of at least three months, single measurements of 
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GFR lower than 60 milliliters per minute (ml/min per 1.73 m2) are considered a risk 
factor for pending or actual development of CKD.21 
Because many areas severely affected by CKDu are agricultural communities in 
warm climates, and because workers in the sugarcane industry brought national attention 
to the epidemic, a large portion of research has focused on occupation and occupational 
heat exposure as a potential cause for CKDu. CKDu has been shown to be associated 
with agricultural work, an additional consideration being lack of shade available during 
breaks from work.22 However, there is also evidence for CKDu in occupations outside of 
agriculture that also have high heat risk, such as brickmaking.19,20 The heat hypotheses is 
widely supported by the research community, as the 2015 Second International Research 
Workshop on MeN acknowledged the growing evidence for heat exposure and 
dehydration in manual labor occupations having a primary effect on CKDu rates.23 
Medication Usage & CKDu 
One hypothesized risk factor for CKDu is medication usage.24 It is known that 
certain medications can impact kidney function, whether that be through nephrotoxicity 
or indirectly through physiological alterations such as in thermoregulation.25,26 
Medications could also interact with other risk factors, like heat and dehydration, 
exacerbating kidney damage and furthering disease progression.26 Even if the drug is not 
directly nephrotoxic, effects on thermoregulation could cause enough of a change to harm 
the kidneys indirectly, such as with dehydration and volume depletion.26 This hypothesis 
has also been applied in the context of NSAID use and dehydration contributing to CKD 
development. 24  
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Our study focused on this impact of medication and supplement usage. 
Specifically, we examine the literature for two medication-related hypotheses: a) that 
nephrotoxic medications and supplements consumed in the region may increase 
susceptibility to CKDu, and b) that medications and supplements consumed in the region 
impair thermoregulation, increasing susceptibility to heat among manual laborers, putting 
them at high risk of repeated kidney injury that would lead to CKDu. Medications may be 
consumed by workers that are both nephrotoxic and affect thermoregulation, together 
increasing the consequences for workers experiencing extreme heat. Medication usage 
and heat stress may work independently or together to alter kidney function via these 
factors; considering both alongside each other is important to better understand if and 
how these multiple factors work together to further development of CKDu. This study 
focuses on this relationship through the lens of medication usage and symptom 
presentation at baseline status of the workers in the cohort (Appendix – Figures: Figure 1, 
page 45). 
Our analyses of exposure to medications and kidney function were conducted in a 
cohort of 524 outdoor workers in agricultural and non-agricultural industries enrolled in 
the Mesoamerican Nephropathy Occupational Study (MANOS) led by Boston University 
researchers. The workers were located in El Salvador, working in sugar cane, corn, or 
construction and Nicaragua, working in sugarcane, plantains and brick making industries.  
We conducted an exploratory analysis to investigate potential associations 
between self-reported medication usage, self-reported symptoms presentation, and kidney 
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function on short-term and long-term timelines. Sub-variables that may modify these 
relationships were also considered, such as country, industry, and age.  
When considering different avenues of impact within the body for hypothesis; the 
study focused on: 1) direct nephrotoxicity and 2) thermoregulation effects 
(acknowledging the prevalent evidence for heat stress in the current literature). First, we 
provide an overview of the literature on Medications and CKD, and Medications and 
Thermoregulation, organized by category of medication. 
 
Specific Aims 
We will accomplish the following specific aims: 
1. Summarize medication usage and symptom presentation across age, industry, and 
country in 524 MANOS participants in El Salvador and Nicaragua. 
2. Examine self-reported short-term and long-term medication usage among  524 
MANOS participants and their associations with kidney function, represented as 
the estimated glomerular filtration rate. 
3. Examine self-reported short-term and long-term symptoms experienced by 
MANOS participants and their association with kidney function, represented as 
the estimated glomerular filtration rate. 
4. Evaluate how covariates of age, industry, and country modify the relationships 




Review of the Literature 
Overview of Mechanisms of renal and thermoregulatory impairment via medication 
The mechanisms by which medications adversely affect the kidneys and 
thermoregulation, individually and combination with other drugs, are summarized in 
Appendix – Tables: Table 1. Several of these mechanisms are related to prostaglandin 
expression and the cyclooxygenase (COX) enzymes, where the specificity of these 
inhibitions is important to note. Prostaglandins are crucial signaling agents that help 
control vasodilation, activation of platelets, inflammation, and fever in the body, among 
several other important tasks. Cyclooxygenase (COX), otherwise known as 
prostaglandin-endoperoxide synthase, catalyzes the production of prostanoids, which 
include prostaglandin, from arachidonic acid. There are three types of COX enzymes: 
COX-1, which protects the GI tract against acid damage; COX-2, which connects to 
fever, pain, and inflammation; and COX-3, whose purpose is currently not clear.27 While 
both aspirin and NSAIDs, such as ibuprofen, can inhibit  COX-1 and COX-2, 
acetaminophen appears to inhibit only COX-3.27 This is important to consider in the 
context of kidney disease, as COX-2 is highly expressed and regulated in the kidneys.28 
Multiple aspects of kidney cell function, such as molecules that help maintain cell 






A medication category that is commonly considered in studies on CKD are 
nonsteroidal anti-inflammatory drugs (NSAIDs), which include the painkillers and anti-
inflammatory medications ibuprofen, diclofenac, and aspirin.30,31 NSAIDs specifically 
are hypothesized to contribute to CKDu.23  
A common use of NSAIDs is to reduce inflammation and pain, doing so by 
inhibiting COX-1 and COX-2 enzymes with relatively equal strength.32 This in turn 




NSAID use can cause nephrotoxicity by altering COX-2 production in the 
kidneys. This inhibits prostaglandin production, inhibiting afferent arteriolar dilation in 
the kidneys, which reduces renal blood flow (RBF). Reducing the renal blood flow to the 
kidneys has multiple damaging mechanisms; it can increase the permeability of the 
intestines and allow more toxins to enter the circulatory system, which potentially leads 
to systemic and kidney tubule inflammation.33 Reduced RBF limits oxygen delivery to 
renal tubules, and also directly lowers GFR, causing renal tissue hypoxia and damaging 
the organ; this damage creates a cyclical effect of reducing oxygen delivery to kidney 
tubules with progressive cellular damage. 33,34 
 At normal therapeutic doses, NSAIDs are not nephrotoxic because the kidneys are 
normally exposed to low amounts of prostaglandins; however, the scenario becomes 
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more complicated when there is  lowered renal blood flow caused by dehydration and 
volume depletion.35 In cases of dehydration, such as from exercise or lowered salt intake, 
the kidney responds to lowered RBF by upregulating production of prostaglandins to 
vasodilate afferent arteriolar blood vessels and increase blood flow, which would 
stabilize the organ’s function.36 NSAIDs inhibiting this reactive process by inhibiting 
renal prostaglandins can be extremely damaging; the lowered RBF can result in 
vasoconstrictive acute renal failure, as well as fluid or electrolyte disorders like 
hyponatremia, hyperkalemia, retaining too much sodium, and resistance to diuretics as a 
result of lost kidney function (loss of ability to regulate electrolyte balance).35–37 
There is some evidence in select human and animal models for associations 
between NSAID usage and lowered eGFR in combination with risk factors involving 
volume depletion and dehydration. Farquhar et al. (1999) conducted a clinical trial on 12 
healthy men and women studying the effect of ibuprofen and acetaminophen usage on 
kidney function in a stressed kidney; they participated in a low sodium diet for three days 
while taking daily dosages of ibuprofen or acetaminophen, and on the fourth day were 
dehydrated and exercised. The study found a small but statistically significant decrease in 
eGFR with participants that used ibuprofen, but not in participants that used 
acetaminophen.36 Ulinski et al. (2004) conducted a clinical observational study where, 
over a period of 20 months, they observed acute renal failure in seven hospitalized 
children that were given ibuprofen for a few days after presenting with vomiting, 
diarrhea, and/or fever; all children were able to fully recover after stopping ibuprofen 
usage and rehydration.38 Mechanistically, the animal model between wildtype and COX-
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2 knockout mice conducted by Küper et al. (2011) presented an interesting link between 
COX-2 and dehydration. Küper et al. (2011) found that dehydration caused increases in 
papillary COX-2 and prostaglandin E2 excretion, but only in the wildtype mice; in 
addition, the knockout mice had higher levels of apoptosis markers in kidney tubule 
epithelial cells, indicating that COX-2 has a role in conserving body fluid volume.39 
Because NSAIDs are a COX-2 inhibitor, if dehydration is triggering COX-2 expression 
but expression is limited by NSAIDs, this points to possible interactions between 
occupational heat stress, dehydration, and NSAID usage in contributing to kidney 
damage and potentially CKDu development. Select studies are summarized in Appendix 
– Tables: Table 2). 
 
Thermoregulation 
NSAIDs can also affect thermoregulation processes in the body, via COX enzymes 
(Appendix – Tables: Table 3). COX-2, which NSAIDs inhibit, is a rate limiting enzyme 
for synthesis of prostaglandin E2 during febrile thermoregulation. Prostaglandin E2 binds 
to EP3 receptors on GABA neurons and indirectly activates spinal motor outputs that 
increase shivering thermogenesis, brown adipose tissue activation, and tachycardia, all 
which help raise body core temperature as part of the immune response to create a 
fever.40 A review by Foster et al. (2015) also explored evidence for prostaglandin E2 
helping to maintain core body temperature during drops in environmental temperature, 
providing evidence that NSAID inhibit could affect body thermoregulation even in 
healthy individuals.40 In addition, NSAIDS decrease aquaporin-2 (AQP2) protein 
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expression, especially during dehydration. In the case of volume depletion, there is an 
antidiuretic response to try to conserve volume involving the peptide hormone 
vasopressin (antidiuretic hormone: ADH). The response to vasopressin is affected by 
AQP2 expression. Essentially, this means that NSAIDS limit the antidiuretic response, 
which is attempting to mitigate the effects of dehydration, through limiting AQP2 
proteins.41 Select studies on NSAIDs usage and thermoregulation effects are highlighted 
in Appendix – Tables: Table 3. 
 
Acetaminophen 
Acetaminophen is an analgesic that targets the central regulation systems in the 
brain for heat and inflammation; it is commonly used to reduce fever. While the exact 
mechanism of action is under debate, it is hypothesized that acetaminophen reduces 
prostaglandin reduction in the brain by inhibiting Prostaglandin H2 Synthetase (PGHS), 
at its COX site, and stopping the conversion of arachidonic acid to prostaglandins.42 With 
less prostaglandin production in the brain, vasodilation is reduced and leads to less 
inflammation and swelling, therefore reducing pain. Acetaminophen is processed in the 
liver and the kidneys by P450 enzymes, and no toxicity is observed with normal dosage 
levels.43 Additionally, it does not appear to affect prostaglandins in the kidneys.42  
 
Nephrotoxicity 
The majority of evidence on acetaminophen induced nephrotoxicity indicates that 
normal therapeutic dosage of acetaminophen is not associated with acute kidney injury or 
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development of chronic kidney disease. For the most part, epidemiological studies on 
healthy individuals have not found links between acetaminophen and kidney disease or 
statistically significant effects on GFR.36,43 However, a population based case-control 
study by Fored et al. (2001) did find that acetaminophen use increased risk of chronic 
kidney disease by a factor of 2.5, but stated that the cause was unknown and may be from 
a confounding variable.44 In addition, a retrospective case-control study of pharmacy 
claims by Kelkar et al. (2012) found that acute, but not chronic, acetaminophen 
prescription use was associated with renal disease.45 However, the retrospective nature of 
the study provides limitations in connecting acetaminophen directly to chronic kidney 
disease development. Select studies are summarized in Appendix – Tables: Table 4. 
 
Thermoregulation 
Mauger et al. (2014) investigated the effect of acetaminophen on exercise 
capacity core body temperature.46 They conducted “time-to-exhaustion” trials on a cycle 
ergometer in different hot temperatures. After taking acetaminophen, the study found that 
participants cycled for significantly longer, had lower core, skin, and body temperatures, 
and had lower thermal sensation with a constant heart rate. Another clinical trial by 
Foster et al. (2016) also found that core body temperature was reduced during exercise 
with acetaminophen ingestion; however, Coombs et al. (2015) found no change in core 
body temperature with associated with acetaminophen during exercise in their study.47,48 
In comparison, a clinical trial on acute stroke patients by Kasner et al. (2002) showed 
lowered core body temperature, and in fact, increased likelihood for hypothermia, 
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although unlikely to have significant clinical effects.49 These findings bring up an 
interesting notion on the effect of acetaminophen on individuals under heat stress. If 
acetaminophen is allowing people to exercise more and feel heat less, does that increased 
exercise tolerance promote more dramatic dehydration, and therefore harmful effects of 
heat stress? Does a longer time to exhaustion, even with lower core temperatures, also 
prolong harmful effects of dehydration and potentially lower kidney function? 
Acetaminophen’s effect on thermoregulation in the body, even if beneficial under heat 
stress, may be setting up other risk factors to have more harmful effects on the body in 
the development of CKDu. Select studies are summarized in Appendix – Tables: Table 5. 
 
Diuretics 
Although each diuretic medication can vary slightly in mechanism, diuretics, in 
general, inhibit kidney tubule transporters for ions, such as sodium, potassium, and 
chloride, in order to halt their reabsorption and promote sodium and water loss.26 
Traditionally, diuretics are used to treat conditions that require the effective circulating 
volume to lower to maintain proper body functions, like hypertension, kidney disease, 
and heart failure. 
 
Nephrotoxicity 
With regards to nephrotoxicity, hypovolemia from diuretics can cause reduced 
blood flow to the liver and kidneys, and therefore reduced clearance of medicines; this 
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can cause renal damage.26 Appendix – Tables: Table 6 summarizes select studies on 
diuretics, nephrotoxicity, and thermoregulation effects. 
 
Thermoregulation 
Diuretics are commonly associated with heat related issues because of their 
antihypertensive, volume depleting effects. Because the purpose of the drug is to remove 
water and sodium from the body, it makes sense that they could exacerbate heat related 
illness from causes such as dehydration. Studies have also shown that diuretic usage 
decreases exercise tolerance by promoting dehydration, which negatively affects the 
cardiovascular and thermoregulation systems.50 Appendix – Tables: Table 6 summarizes 
select studies on diuretics, nephrotoxicity, and thermoregulation effects. 
 
Nephrotoxicity & Thermoregulation effects of Aminoglycoside Antibiotics, Analgesic 
Opioids, Potassium Supplements, and Urinary Antiseptics 
Other medications categorized in this study have been established as having 
nephrotoxic effects and also have some associated research regarding and 
thermoregulation effects (Appendix – Tables: Table 7). Several studies describe cases of 
overdose and acute renal injury which, despite extending beyond the typical situation of 
normal dosage in development of chronic kidney disease, are still important to note. 
Aminoglycoside antibiotics exhibit nephrotoxicity from drug uptake into the renal 
proximal tubular cells via lysosomes, eventually leading to cell necrosis and GFR 
decrease.51,52 For analgesic opioids, a review by Mallappalli et al. (2017) found an 
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association between opioid use and acute and chronic kidney disease; risk of kidney 
damage was also increased with dehydration, with resulting reduction of renal clearance 
from lowered RBF potentially causing drug toxicity.26,53 Other factors to note in extreme 
cases are potential hyperkalemia from potassium supplements and kidney damage from 
urinary antiseptic overdose.54,55 Select studies are summarized in Appendix – Tables: 
Table 7. 
 
Combination Effects with Multiple Medications 
When investigating  any effects of medication usage, it is important to 
acknowledge that medications may be taken in combination, and therefore may result in 
physical reactions not previously considered with individual drugs. A key theme in the 
literature on combination effects of medications considered in this study is the 
consequences of using NSAIDs and diuretics simultaneously. Because NSAIDs reduce 
vasodilation of the kidney’s afferent arterioles via COX and prostaglandin production 
inhibition, they counteract the sodium and water loss normally achieved from the 
antihypertensive effect of diuretics.56 Other effects from diuretic combination are that 
diuretics, alone and in combination with other drugs, can increase the risk of heat related 
illness.26 For thermoregulation, Veltmeijer et al. (2017) also found that combined usage 
of acetaminophen and ibuprofen limited the core body temperature increase during 
exercise, suggesting that prostaglandins could relate to NSAID modification of 
thermoregulation; however, the combined medication study indicates that more research 
is needed to find a direct cause.57 Appendix – Tables: Table 8 summarizes select 
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combination effects from using multiple drugs simultaneously and highlights some 
effects that may impact the development of chronic kidney disease. Although this study 
did not note combined usage of medication among cohort participants, this presents an 
opportunity for future investigation.  
 
Study Rationale 
It is possible medication usage may contribute to the development of CKDu in 
Nicaragua and El Salvador. Mechanistically, the medication categories discussed all have 
a connection to altering thermoregulation and/or renal outcomes in the body; however, 
the present literature does not have a clear message regarding the significance of these 
medications in relation to CKDu. We hypothesize that when combined with heat stress 
experienced regularly, such as during work, the negative effects of medication usage will 
significantly exacerbate kidney damage. Although our analysis did not utilize data 
directly measuring heat stress, it was important to have this topic inform our hypothesis 
as it constitutes a large portion of the research literature and is a significant component of 
daily life for the study’s cohort population. Prominent examples in the literature include 
damaging effects of NSAIDs when individuals are dehydrated. In including the 
discussion on heat stress as we investigated medication usage and kidney function, we 
have included medications, such as acetaminophen, that do not directly affect the kidneys 
but may indirectly have a negative effect on renal outcome through altered 
thermoregulation. Our analysis investigated associations between medication usage, 
symptom presentation, and kidney function in a cohort of workers in El Salvador and 
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Nicaragua to examine the relationship between medication usage and chronic kidney 







This study analyzed data from 524 participants in the Mesoamerican Nephropathy 
Occupational Study (MANOS). Collaborating with investigators in El Salvador and 
Nicaragua, the Boston University School of Public Health Research Group for the Study 
of Chronic Kidney Disease started the MANOS longitudinal cohort study on chronic 
kidney disease in Central America, otherwise known as Mesoamerican Nephropathy, in 
January 2018.6 Workers were recruited across a range of industries in El Salvador and 
Nicaragua including sugarcane workers, corn and construction in El Salvador, and 
sugarcane, artisanal brick makers, and plantain in Nicaragua. Workers in the cohort were 
all male and between the ages of 18-45. All provided informed consent before 
participating in the study. These analyses used data from participants who provided blood 
samples during the first and second rounds of collection, limiting the sample size to 524 
participants from the MANOS cohort. 
Data Collection 
Baseline data for medication usage, frequency of usage symptom presentation, 
and frequency of presentation were collected via questionnaire, administered by trained 
interviewers in January - May of 2018. For medication usage, participants were asked 
how many times they had used the drug in the past year and past week before the time of 
questionnaire, and for symptom presentation, if they had experienced said symptoms in 
the past 3 months and 24 hours before the time of questionnaire. Workers provided blood 
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samples at baseline at the end of the three day monitoring period (round 1 collection) and 
during a follow up round of data collection approximately six months later (round 2 
collection) to measure serum creatinine and estimate GFR. Estimated GFR was 
calculated using the CKD-Epidemiology Collaboration equation.58  
In the baseline questionnaire, workers were asked about their usage of eight types 
of medication: acetaminophen, aminoglycoside antibiotics, analgesic opioids, diuretics, 
non-steroidal anti-inflammatory drugs (NSAIDs), aspirin (a subset of NSAIDs), 
potassium supplements, and urinary antiseptics. Aspirin usage was recorded separately 
from other NSAIDs because of its different mechanism of action, as aspirin irreversibly 
inhibits COX enzymes while other NSAIDs are reversible inhibitors.59 Workers were also 
asked about the use of  different specific NSAIDs. Data were collected on a) if they had 
ever used the medication b) number of times used in the last 1 year and c) number of 
times used in the last week, as well as d) the reason for taking the medication. 
 Workers were asked to rate their general health and indicate if they had 
experienced the following 19 symptoms in a) the past 3 months and b) within the last 24 
hours: lower abdominal pain, back pain, flank pain, chistata (a set of symptoms that can 
include back pain and burning and pain when urinating), frequency of urination, fever or 
chills, muscle cramps, headache, lack of sweating, nausea, vomiting, palpitations, 
shortness of breath, lightheadedness or dizziness, fainting, confusion, delirium, decreased 
urine quantity, and dry mouth. They were also asked if they had ever been diagnosed 




 Analysis was structured around medication usage, symptom presentation, and 
kidney function via eGFR. Summary statistics of medication usage, symptoms, and eGFR 
were calculated for the 524 participants across age, industry, and country. Summary 
statistics were calculated for both round 1 and mean eGFR across industries, as well as 
counts of workers with eGFR greater than or equal to 90 ml/min per 1.73 m2, between or 
equal to 60 and 90 ml/min per 1.73 m2, and below 60 ml/min per 1.73 m2. An estimated 
GFR of below 60 ml/min per 1.73 m2 can indicate chronic kidney disease development. 
Medication usage was summarized by the number and percent of workers that used the 
medication within the past 1 week, 1 year, or no usage in the past year prior to baseline in 
each industry. Symptom presentation was summarized by the number and percent of 
workers that experienced the symptom in the past 24 hours, 3 months, or did not 
experience in the past 3 months prior to baseline. 
Two separate predictive models were constructed: one with medication usage and 
kidney function, and one with symptom presentation and kidney function. This structure 
allowed us to  interpret results without the possibility of a confounding effect from either 
symptom or medication use variable (Appendix – Figures: Figure 2, page 46). Analyses 
were also separated into a short-term and a long-term time frame. For medication usage, 
short-term time frame was within 1 week of baseline and long-term was within 1 year of 
baseline. For symptom presentation, short-term was within 24 hours of baseline and long-
term was within 3 months of baseline. For the outcome, eGFR, we also created short- and 
long-term outcomes. For short-term analyses, round 1 eGFR was used. For long-term 
 
21 
analyses, a cross sectional value was used by averaging the eGFR from round 1 and 
round 2 together for each worker. 
Crude associations between hypothesized predictors and eGFR outcomes were 
conducted with chi-square distributions and two-sample t tests with equality of variance F 
tests to better understand the patterns of eGFR among the full cohort. Mean differences 
of eGFR values were calculated between workers by medication usage in the past 1 week 
and past 1 year leading up to the time of the baseline questionnaire with 95% confidence 
intervals. Mean differences of eGFR were also calculated for workers by presentation of 
symptoms in the past 24 hours and 3 months prior to baseline; 95% confidence intervals 
were also calculated. Tests were applied to categories that had a sample size of a least 10 
workers for each time frame of usage (1 week and 1 year) or presentation (24 hours and 3 
months). Associations were calculated for: 1) short-term usage and presentation with 
round 1 eGFR values to reflect short-term kidney function, and 2) long-term usage and 
presentation with mean eGFR values to reflect cross sectional association.  
Industry, country, and age were included as covariates in multivariable logistic 
regression models examining medication usage and kidney function, and symptom 
presentation and kidney function. Predicted outcome was an eGFR value of less than 60 
ml/min per 1.73 m2. Models were repeated for both short-term time frames using round 1 
and mean eGFR, and long-term time frames using mean eGFR.  
SAS version 9.4 (SAS Statistical Software, Cary, NC) was the software used for 
analyses. P-values were recorded for each test run, and noted for alpha levels of 0.20, 




Study cohort characteristics  
Our study population of 524 workers consisted of 250 workers in El Salvador 
(48%) and 274 in Nicaragua (52%). Sugarcane was the most common industry in El 
Salvador with 105 out of 250 workers (42%), followed closely by corn (103 workers, 
41%) and then lastly construction (42 workers, 17%). Industry distribution in Nicaragua 
followed a similar pattern; sugarcane was also the most common  with 119 out of 274 
workers (43%), 103 in  brick making (38%) and 52 in plantains (19%).  
All participants were male with a cohort mean age of 29.4 +/- 7.4 years, ranging 
from 18 to 45 years of age. There was a significant difference in mean age among at least 
one of the six industries when tested by single factor ANOVA (p < 0.05). Construction 
workers in El Salvador had the highest mean age at 31.2 years, followed by brick workers 
in Nicaragua (31.0). Workers in corn in El Salvador had the lowest mean age at 27.6 
years. 
 
Differences in kidney function by country and industry 
The cohort’s mean round 1 eGFR was 106.3 ml/min per 1.73 m2, while for round 
1 and 2 eGFR mean values was slightly lower at 105.3 ml/min per 1.73 m2. eGFR values 
differed across country and industry for both measurements. For round 1 eGFR, 
sugarcane workers in Nicaragua had the highest mean value across industries in both 
countries with 112.9 ml/min per 1.73 m2, followed by construction workers in the cohort 
in El Salvador with 111.9 ml/min per 1.73 m2. In contrast to the sugarcane workers in 
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Nicaragua, sugarcane workers in El Salvador had the lowest round 1 eGFR values across 
all industries, with a mean of 97.7 ml/min per 1.73 m2. Brick workers had the second 
lowest round 1 eGFR with a mean of 102.3 ml/min per 1.73 m2. When comparing the 
round 1 eGFR to round 1 and 2 mean eGFR patterns, construction in El Salvador (112.3 
ml/min per 1.73 m2) and sugarcane in Nicaragua (111.4 ml/min per 1.73 m2) still have the 
highest round 1 eGFR mean, although construction had the highest value. El Salvador 
sugarcane (98.1 ml/min per 1.73 m2) and brick workers in Nicaragua (100.7 ml/min per 
1.73 m2) still had the lowest means as well among the industries for round 1 and 2 mean 
eGFR. There was a significant difference in mean eGFR among at least one of the six 
industries when tested by single factor ANOVA (p = 0.002, α <0.05).  
For round 1 eGFR data, 417 participants, or about 80%, had a mean eGFR above 
90 ml/min per 1.73 m2, and 56 participants (11%) had mean eGFR values between 60 and 
90 ml/min per 1.73 m2. The remaining 51 workers (9%) had mean eGFR values of less 
than 60 ml/min per 1.73 m2. The distribution was similar for workers’ mean eGFR across 
the two rounds, with 414 (79%), 61 (12%), and 49 (9%) workers in the > 90 ml/min per 
1.73 m2, 60 to 90 ml/min per 1.73 m2, and < 60 ml/min per 1.73 m2 categories 
respectively. Estimated GFR data is summarized in Appendix – Tables: Table 9. 
 
Cohort medication usage characteristics 
Medication usage patterns were consistent across both the 1 year and 1 week time 
frames leading up to baseline. Acetaminophen and NSAIDs (across the different types 
excluding aspirin) were the top medications used within the last year prior to baseline, 
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with 297 and 278 members of the cohort self-reporting usage at least once, respectively. 
Use of other medications was much lower; aspirin and urinary antiseptics were the next 
highest usage in the past year with 33 members self-reporting usage at least once for each 
category.  
This pattern was consistent within usage of 1 week prior to baseline; 
acetaminophen and NSAIDs were the most medications used with 112 and 88 members 
reporting usage respectively, followed by aspirin with 17 workers reporting and urinary 
antiseptics with 8 workers reporting. Acetaminophen and NSAID usage were consistently 
the most common cohort wide characteristic across a short-term and long-term timeline, 
especially when considering the large drop off in usage among the other medication 
categories. Values are summarized in Appendix – Tables: Table 10. 
 
Cohort symptom presentation characteristics 
Patterns of symptom presentation were also consistent across the short-term (24 
hour) and long-term (3 month) timeframe prior to baseline, although not as drastically 
different across several of the symptom categories. Within 3 months of baseline, the top 
reported symptoms were 1) back pain (n=315), chistata (n=227), and headache (n= 225). 
The average number of workers reporting for a select symptom was 93, but there was a 
wide range of reporting; delirium was the lowest reported (n=5), but 5 other symptoms in 
addition to the top three reported numbers over the average: muscle cramps (n=130), 
flank pain (n=119), dry mouth (n=100), increased urination frequency (n=99), and lower 
abdominal pain (n=97).  
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The top three symptoms exhibited within 24 hours of baseline among the cohort 
were also back pain, headache, and chistata, but headache rose from third highest to 
highest in the short-term time frame with 82 reporting, followed by chistata (n=66) and 
back pain (n=49). The average number of participants who reported symptoms within 24 
hours was significantly lower at around 29. Levels were as low as 2 workers reporting 
delirium, which remained the least common symptom, but the same 8 symptoms that 
were at the top of reporting for 3 months were also the top 8 for 24 hour presentation, 
now ordered by flank pain (62), lower abdominal pain (49), dry mouth (44), increased 
urination frequency (33), and muscle cramps (33). Overall, while short-term presentation 
levels were much lower than long-term presentation levels, the symptoms that were 
reported the most and least remained relatively constant across both timeframes. Values 
are summarized in Appendix – Tables: Table 11.  
 
Associations between medication usage and kidney function in MANOS  
To evaluate the relationship between medication usage and kidney function in the 
cohort, crude association analyses were run in the form of chi-squared tests and two-
sample t tests, and adjusted associations were examined with logistic regressions. Chi-
squared tests were only run for acetaminophen and NSAIDs, as the sample size was too 
low for the remaining 6 medication categories to have the model run with accuracy. 
Distribution was evaluated by worker’s medication usage and eGFR (using the round 1 
value for 1 week usage and the mean of rounds 1 and 2 for 1 year usage) above or below 
60 ml/min per 1.73 m2. For both 1 week and 1 year usage, the percentage of participants 
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that used acetaminophen did not differ by eGFR status of above or below 60 ml/min per 
1.73 m2 (1 week usage: 2 (1, N = 524) = 0.16, p > 0.05; l year usage: 2 (1, N = 524) = 
0.005, p > 0.05) (Appendix – Tables: Table 12). The percentage of participants that used 
NSAIDs in 1 week did differ by eGFR status (2 (1, N = 524) = 3.06, p < 0.05), but there 
was no association between usage and eGFR in the chi-squared test on 1 year usage (2 
(1, N = 524) = 0.09, p > 0.05) (Appendix – Tables: Table 12). 
In the two-sample t tests, there was a significant difference in round 1 eGFR 
between groups that used and did not use NSAIDs within 1 week of baseline; mean round 
1 eGFR for workers that used NSAIDs was 7.8 ml/min per 1.73 m2 lower than the group 
of workers that did not use NSAIDs within 1 week of baseline (95% confidence interval -
11.6 to -3.9, p-value < 0.05). This difference went away in the test of difference over the 
long-term. In all other medication categories, there was no significant differences from 
short-term usage of the medications on mean eGFR in the cohort. No test was run for 
analgesic opioids, aminoglycoside antibiotics, diuretics, potassium supplements, or 
urinary antiseptics because the usage sample size was too small to yield accurate results 
(Appendix – Tables: Table 13). When looking at long-term usage of the medications, 
which was within 1 year of baseline, two-sample t test associations between 1 year usage 
and cross sectional round 1 and 2 mean eGFR showed that there was no longer a 
significant difference between NSAID usage and eGFR. However, there was a significant 
difference at an alpha level of 0.20 from potassium supplement usage on round 1 and 2 
mean eGFR; mean eGFR was 15.2 ml/min per 1.73 m2 lower in the usage group 
compared to workers who did not use potassium supplements in the last year prior to 
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baseline (95% confidence interval -32.8 to 2.5, p-value < 0.15) (Appendix – Tables: 
Table 13). 
 Logistic regressions were run for each medication category to examine the 
association of medication usage and eGFR < 60 ml/min per 1.73 m2, adjusting for age, 
country, and industry. Medication usage within one week before baseline was not 
significantly associated with round 1 eGFR values < 60 in the regressions (Appendix – 
Tables: Table 14). However, usage of potassium supplements within 1 year of baseline 
was significantly associated with a round 1 and 2 mean eGFR value < 60 ml/min per 1.73 
m2. Workers who reported potassium supplement usage within 1 year of baseline had 
6.27 relative odds of round 1 and 2 mean eGFR be < 60 ml/min per 1.73 m2, compared to 
workers that did not use potassium supplements within 1 year of baseline (95% 
confidence interval 1.40 to 27.99, p-value < 0.05) (Appendix – Tables: Table 14). 
 
Associations between symptom presentation & kidney function  
Several symptoms were not analyzed in the chi-squared tests, due to small sample 
sizes. For chi-squared tests, the percentage of workers that reported short-term 
presentation of headache, back pain, or flank pain 24 hours prior to baseline data 
collection significantly differed by round 1 eGFR status of either above or below 60 
ml/min per 1.73 m2. Headache had the strongest significance (2 = 5.96, p < 0.05) 
followed by back pain and flank pain, which were moderately significant at higher alpha 
levels of < 0.20 and < 0.10. (Appendix – Tables: Table 15). However, when looking at 
long-term symptom presentation, none of the symptoms presented within 24 hours that 
 
28 
were significantly associated with eGFR were significant when reported within three 
months prior to baseline. 
In crude, unadjusted associations with two-sample t tests, there were several 
significant differences (p < 0.05) in mean eGFR for workers that did present a particular 
symptom, compared to workers that did not present that symptom. For short-term 
presentation within 24 hours of baseline, workers that experienced flank pain, fever, 
muscle cramps, or headache had lower round 1 eGFR compared to workers that did not 
experience that particular symptom (Appendix – Tables: Table 16). Fever had the highest 
mean difference in eGFR; the round 1 mean eGFR of workers that did have a fever was 
13.5 ml/min per 1.73 m2 lower than workers that did not have a fever (95% confidence 
interval -24.9 to -1.9, p-value < 0.05) (Appendix – Tables: Table 16). Muscle cramps had 
the next largest mean difference for the short-term time frame (mean difference -12.8, 
95% confidence interval -22.7 to -2.8, p-value < 0.05) (Appendix – Tables: Table 16). 
Other symptoms had a significant mean difference in round 1 eGFR, but at higher alpha 
levels of 0.10 and 0.20; for example, workers that did experience palpitations within 24 
hours of baseline had an average round 1 eGFR of 18.8 ml/min per 1.73 m2 lower than 
workers with no 24 hour palpitations, with a p-value < 0.10 (Appendix – Tables: Table 
16).  
However, the round 1 and 2 mean eGFR of workers that did report lack of 
sweating in the past 3 months was 12.2 ml/min per 1.73 m2 lower than workers who did 
not report the symptom (95% confidence interval -20.9 to -3.5, p-value < 0.01). This is an 
increase in significance level from short-term presentation (Appendix – Tables: Table 
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16). In addition, while short-term chistata presentation did not indicate a significant 
difference in round 1 eGFR, the round 1 and 2 mean eGFR of workers that did 
experience chistata 3 months before baseline (long-term) was 11.2 ml/min per 1.73 m2 
higher than workers that did not experience chistata 3 months before baseline (95% 
confidence interval -11.7 to -10.6, p-value < 0.0001) (Appendix – Tables: Table 16). Out 
of the symptoms with significant difference in mean eGFR, chistata was the only 
symptom where workers that experienced it had a significantly higher mean eGFR, rather 
than a lower eGFR compared to workers that did not experience the symptom ( Appendix 
– Tables: Table 15 and Table 16). 
 In the logistic regressions, symptom presentation within 24 hours before baseline 
was not significantly associated with round 1 eGFR values < 60 ml/min per 1.73 m2 in 
the regressions for any of the 19 symptoms (at an alpha level of 0.05) (Appendix – 
Tables: Table 17). Short-term presentation of fever, muscle cramps,  palpitations each 
had moderately significant  associations with an increased relative odds of a round 1 
eGFR <60 ml/min per 1.73 m2 with p-value < 0.20. Short-term presentation of lower 
abdominal pain predicted a 0.40 (95% CI 0.13 – 1.29) decrease in relative odds for 
having round 1 eGFR < 60 ml/min per 1.73 m2 (Appendix – Tables: Table 17). This was 
consistent in 3 month presentation, with a 0.35 decrease in relative odds for eGFR < 60 
ml/min per 1.73 m2 (95% CI 0.13 – 0.99) and a stronger p-value < 0.05. Workers that 
report chistata within 3 months of baseline also had a decreased relative odds 0f 0.37 for 
eGFR < 60 ml/min per 1.73 m2 (95% CI 0.18 to 0.77, p-value < 0.05) (Appendix – 





In a cohort of male workers from Nicaragua and El Salvador participating in the 
Mesoamerican Nephropathy Occupational Study, we explored associations between 
medication usage, symptom presentation, and kidney function through baseline. We 
controlled for age, industry, and country to further investigate these associations. We also 
compared short-term to long-term medication usage and symptom reporting, using 
baseline and mean eGFR from the two rounds of data collection, to capture a short- and 
long-term effect on kidney function, although these are all cross sectional analyses.  
Acetaminophen and NSAIDs were by far the most commonly used medication 
categories across the cohort in both short-term and long-term time frames. For symptoms, 
the distribution of presentation was slightly less drastic, but back pain, headache, and 
chistata remained the top symptoms experienced on both a short-term and long-term 
scale before baseline. However, there was not a clear pattern of association between these 
two main predictors and kidney function.   
For short-term medication usage within 1 week of baseline, NSAIDs exhibited a 
significant mean difference when not adjusting for age, country, and industry, but in the 
logistic regression that adjusted for these demographics, this association was no longer 
significant. No other medications showed significant association with short-term usage 
on round 1 eGFR, indicating that there is likely no direct effect from medication usage on 
lowered kidney function. It was interesting to note that although acetaminophen was the 
highest used drug in both short and long-term timeframes, there was no association with 
lower or higher kidney function throughout crude and adjusted analysis in both 
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timeframes. This suggests acetaminophen usage has neither a directly protective nor 
damaging effect on kidney function. Because acetaminophen does not affect COX-1 and 
COX-2, where COX-2 is expressed in the kidneys, and only potentially affects COX-3, 
this finding is consistent with knowledge on base nephrotoxicity.27 However, it is 
interesting to consider alongside past studies showing that acetaminophen can lower core 
body temperature changes during exercise, such as in the study by Mauger et al. (2014); 
while the findings in this study show that acetaminophen’s mechanisms do not directly 
alter kidney function, there is an opportunity for further research to explore indirect 
effects, especially because of evidence of the drug’s effect on thermoregulation.46 
For long-term usage within 1 year of baseline, only potassium supplements were 
significantly associated with the outcome. When controlling for age, industry, and 
country, potassium supplement usage showed a significant increase in relative odds of 
having eGFR below 60 ml/min per 1.73 m2 at an alpha level of 0.05. This finding 
highlights the limitations of cross-sectional analyses and raises questions regarding the 
directionality of the association with kidney function. In other words, Are workers taking 
the potassium because of lowered kidney function, or is the usage causing lowered 
kidney function? There is also the question of workers medicating for certain symptoms 
that may be a result of lowered kidney function. In the case of potassium supplements, 
chronic kidney disease can cause kidneys to not be able to process potassium, leading to 
hyperkalemia and organ damage.59 Workers with lowered kidney function could be 
taking potassium supplements because of the low kidney function, rather than the 
potassium supplements contributing to low kidney function (i.e., reverse causality).  
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For short-term symptom presentation, flank pain, muscle cramps, headache, and 
fever were all significant at an alpha level of 0.05 for lower mean round 1 eGFR. 
However, the significance of those associations was less in the adjusted logistic 
regression; no one symptom significantly predicted for eGFR less than 60 ml/min per 
1.73 m2 at an alpha level of 0.05, with palpitations being the only symptom associated at 
an alpha level of 0.10. This indicates that on a short-term basis, 24 hour symptom 
presentation does not likely show lowered kidney function, nor is likely to be an accurate 
predictor of  CKD.  
In long-term presentation over 3 months prior to baseline, chistata stood out as 
significantly associated (p-value < 0.05) in both crude and adjusted associations, but the 
workers that had chistata had a higher eGFR and were less likely to have an eGFR below 
60 ml/min per 1.73 m2 in adjusted associations. It was interesting that presentation of lack 
of sweating and lightheadedness were significant in crude associations for lower mean 
eGFR but not in adjusted, yet presentation of lower abdominal pain was significant only 
in adjusted associations for decreased relative odds of having eGFR below 60 ml/min per 
1.73 m2. Because chistata is set of symptoms uniquely associated with CKD in the 
region, this finding warrants further investigation. The association of kidney function 
with symptoms related to heat related illness, such as lack of sweating and 
lightheadedness, on a long-term basis is also a point for further study, especially when 




A main limitation of this study was sample size of the groups of workers that used 
the medication or experienced a particular symptom, which meant we were not able to 
conduct frequency distribution tests on several of the categories. To perform a fully 
exploratory analysis, we considered the associations at different alpha levels of 
significance.  
One significant limitation of this study involved studying the relationship between 
medication and kidney function, and symptoms and kidney function, as separate models, 
so as not to confound directionality of effect among the predictors. Medications can be 
used for symptoms and symptoms can be a result of kidney function, or medications 
could cause symptoms that could exacerbate lowered kidney function. This study serves 
as an exploratory analysis investigating medications, symptoms, and kidney function, but 
there is an opportunity for further study on how medications and symptoms relate to both 
nephrotoxicity and heat stress’s association with kidney function. 
Future analyses  
In order to build on the findings in this study on medication usage and kidney 
function in the context of CKDu in Central America, future analyses would benefit from 
considering more factors related to heat stress. Looking at water consumption and 
dehydration, for example, could potentially provide insight into the interaction between 
heat stress and medication usage on kidney function. In addition, it could be useful to 
model the effects of medication in combination on kidney function to see if workers that 
took multiple medications had a difference in their eGFR. These analyses could be 
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repeated for symptoms, as well as finding patterns between medications used and 
symptoms experienced to help better describe the cohort’s medical history characteristics. 
Investigating the interaction of medication, heat exposure, and dehydration via more 
interaction analyses in the MANOS cohort study would be a beneficial opportunity to 
expand our understanding of medication and CKDu development.  
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APPENDIX – FIGURES 
 
 
Figure 1. Diagram representation of medication usage, heat stress, and their 






Figure 2. Main variables and structure of analysis. 2a. Hypothetical relationship 
among main predictors of medication usage and symptom presentation and outcome of 
kidney function. 2b. Analysis is structured with two separate models to remove potential 
interacting effects between medication usage and symptom presentation for the purpose 
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APPENDIX – TABLES 
 
Table 1 (Part 1). Summary of medications and their mechanisms of toxicity on renal 
function, thermoregulation, and adverse effects of medications on renal function or 
thermoregulation in combination.  
Medication 
Category 
Renal function Thermoregulation 
Combination effect 
with other medication 




levels in the brain but 
has not been shown to do 
so in the kidney.42 
 
Reduce core temperature 
during normal activity 
and in exercise. 47 It is 
hypothesized to mediate 










Taken up by proximal 
tubular cells into 
lysosomes. These 
develop into lysosomal 
phospholipidosis, which 
leads to cell necrosis. 
Effects include tubular 
regeneration, peritubular 
proliferation, and 
decrease in eGFR.51 
No literature found on 
the topic. 
 




There is an association 
between opioid use and 
acute and chronic kidney 
disease.53 
Reduced renal clearance 
from dehydration can 
cause analgesic opioid 
toxicity.26 
Analgesic opioids can 
result in sedation and 
cognitive impairment, 
leading to altered 
perception of hot 
weather. Anticholinergic 
opioids can cause altered 
central thermoregulation 
and hypotension.26 






Table 1 (Part 2). Summary of medications and their mechanisms of toxicity on renal 
function, thermoregulation, and adverse effects of medications on renal function or 
thermoregulation in combination  
Medication 
Category 
Renal function Thermoregulation 
Combination effect 
with other medication 






causes reduced blow 
flow to the liver and 
kidneys and reduced 
clearance of medicines 
and toxins. For 
nephrotoxicity, this leads 
to renal impairment, 




dehydration. This causes 
reduced blow flow to the 
liver and kidneys and 
reduced clearance of 
medicines and toxins. 
For thermoregulation, 
this leads to electrolyte 
imbalance and reduced 
thirst sensation, which 
along with renal 
impairment increases 
risk of hyperkalemia.26 
Especially in combined 




have higher risk of HRI 
during higher 
temperatures.26 COX 
inhibitors reduce the 
antihypertensive effects 
of ACE inhibitors, which 




release, leading to 
reduced vasodilation at 
the glomerulus in the 
kidney. Reduced blood 
flow can lead to kidney 
tubule damage.37 Can 
also cause 
fluid/electrolyte 
disorders like sodium 




production. The specific 
prostaglandin E2 (PGE2) 
normally mediates heat 
generation in 
thermoregulation.40 
Specific to aspirin, 
aspirin can limit reflex 
cutaneous vasodilation 
and the therefore ability 
to cool off.60 It can also 
raise core temperature 
more during heat stress 
compared to not taking 
the drug with and 
without exercise.61 




of ACE inhibitors, which 





In patients with CKD, 
hyperkalemia is a 
common problem that 
can be caused by 
supplements.54 
No literature found on 
the topic. 
 





There had been an acute 
renal failure with 
overdose in case study.55 
No literature found on 
the topic. 
 





Table 2 (Part 1). Selection of studies on NSAIDs, renal outcome, and risk factors 





















This clinical observational study found that 
15 inpatients aged an average of about 15 
years were referred for acute kidney injury; 
all had taken ibuprofen, and some had 
taken naproxen. While none of the patients 
had underlying kidney disease when 
admitted, the estimated GFR at the peak of 
the patient’s kidney failure was 38.2 ± 20.5 
ml/min per 1.73 m2, improving to 134 ± 
26.2 ml/min per 1.73 m2). It took an 
average of 37 days to normalize serum 
creatinine levels. This indicates that the 
majority of patients had prolonged renal 
damage and provides evidence for 












This clinical observational study found that 
therapeutic doses of NSAIDs, even with 
moderate volume depletion, can be 
potentially harmful to the kidneys. The 
hospital featured in the study had seven 
children in a period of 20 months that had 
diarrhea, vomiting, and/or fever and were 
treated with ibuprofen for a few days and 
then had acute renal failure. After stopping 
NSAID treatment and rehydrating, all 
















In this clinical case study, a 14 year old 
boy experienced acute renal failure after 
aortic value surgery after taking aspirin 
and ibuprofen for about a week. Dialysis 
was required, and a kidney biopsy had 
inflammatory infiltrate matching acute 
tubulo-interstitial nephritis. There were 






Table 2 (Part 2). Selection of studies on NSAIDs, renal outcome, and risk factors 





















AKI Dehydration In an animal model comparing wildtype 
and COX-2 knockout mice renal damage, 
dehydration caused strong increases in 
“papillary COX-2 expression, PGE2 
excretion, and Bad phosphorylation” only 
in the wildtype mice. Apoptosis marker 
caspase-3 was significantly higher in 
tubular epithelial cells in COX-2 knockout 
mice, indicating a role of Bad 














CKD Dehydration An animal model using rofecoxib (a 
selective COX-2 inhibitor) showed that 
chronic inhibition of COX-2 in dehydrated 
rats reduces heat shock protein 70 (HSP70) 
expression in the renal medulla, making 
papillary cells vulnerable to damage from 
high urea concentrations (Neuhofor 2004). 
HSP70 is stimulated by prostaglandins; the 
study supports that COX-2 inhibition may 






and ibuprofen on 
renal function in 
the stressed 
kidney 
AKI Heat stress 
Exercise 
Dehydration 
This clinical trial looked at effects of 
acetaminophen and ibuprofen on renal 
function with 12 healthy men and women 
participants. They first underwent a low 
sodium diet, then dehydration, then 
exercise in the heat over 4 days. The 
combined scenarios caused significant 
decreases in renal plasma flow, GFR, and 
sodium excretion. They found that over the 
counter ibuprofen had small but 
statistically significant effects on GFR 
during exercise in a dehydrated and low 
sodium condition, while over the counter 
acetaminophen did not have any 














In this clinical trial involving with 24 
participants with normal blood pressure, 
short-term, normal dose of NSAIDs did 
not significantly alter blood pressure or 
renal function in young and elderly 





Table 2 (Part 3). Selection of studies on NSAIDs, renal outcome, and risk factors 





















This clinical trial was a randomized, 
controlled crossover study involving 12 
healthy male volunteers. They found that 
diclofenac at therapeutic dosage over 3 
days did not have effect on clearance 
(creatinine, inulin, PAH) and did not 
decrease glomerular filtration or renal 









A case-control study in Sweden, with 
926 patients with newly diagnosed renal 
failure and 998 control subjects, found 
that regular use of acetaminophen or 
aspirin increases risk of chronic renal 
failure by factor of 2.5, but the causal 





Analgesic use and 
change in kidney 




This prospective cohort study involving 
4,494 US male physicians that provided 
blood samples 14 years apart. They 
found that moderate usage of aspirin, 
acetaminophen, or NSAIDs for pain 
relief did not appear to be associated with 
higher risk of kidney function decline 




Renal failure associated 





This retrospective study searching the 
USA Food & Drug Database’s Adverse 
Event Reporting system found 122 and 
142 cases of celecoxib and rofecoxib 
associated renal failure. They found that 
renal failure in patients could be 





NSAID use and 




One clinical study on traditional CKD 
and NSAID use followed a cohort of 
approximately 10,000 elderly patients 
(mean age 76) to track progression of 
CKD. There was an association between 
NSAID use and increased CKD 
development risk in the cohort; they 
found that patients in the top 10% of 
NSAID usage had a 26% increased risk 
of decreased estimated GFR of more than 
15 ml/min per 1.73 m2.68 
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Table 2 (Part 4). Selection of studies on NSAIDs, renal outcome, and risk factors 























A qualitative analysis of physician and 
pharmacist interviews in northwestern 
Nicaragua suggested that occupational 
heat exposure and dehydration were risk 
factors for CKDu. They also noted that 
individuals were hesitant to hydrate 
because of water contamination 
concerns. They found that kidney 
disease symptoms were often treated 
with NSAIDs, diuretics, and 
antibiotics.69 
Kuo et al. 
(2010) 
Analgesic use and 




CKD Not Covered A cohort study with CKD patients 
found that acetaminophen, aspirin, and 
non-selective (for COX) NSAIDs 
“exacerbate[ed]” effects of CKD, 
consistent with dosage amount. For 
COX-2 inhibitors, only “rofecoxib 





Evaluation of heat 
stress and 
cumulative 
incidence of acute 
kidney injury in 
sugarcane workers 
in Guatemala 
AKI Dehydration Dehydration combined with NSAID 
usage increased the risk of AKI. Study 
by Butler-Dawson et al indicated 
dehydration and low electrolyte 
consumption as risk factors for AKI in a 
study on sugar cane workers in 
Guatemala. The study reported low 
NSAID use but did find a significant 
association between NSAID use and 
post shift specific gravity, an indicator 












CKD Not Covered The study did not find significance 
between NSAID usage and decrease in 
GFR during a 6 month harvest study on 





Table 2 (Part 5). Selection of studies on NSAIDs, renal outcome, and risk factors 











hydration and uric 
acid: a cross-
sectional study in 
workers of three 





CKD Not Covered A cross sectional study on younger 
male Nicaraguan workers across three 
industries did not find an association 




















This study on Mesoamerican 
sugarcane workers developed a model 
to explore the effect of occupational 
heat stress and strenuous work in the 
heat with other risk factors, including 
NSAID use, on CKD development. 
There results indicated that 
inflammation and hyperuricemia were 
linked to kidney injury. The risk of 
kidney injury was increased by 
rehydrating with sugary drinks and 
NSAID usage, while electrolyte 
sodium intake had a protective effect. 
They also found kidney injury 





Table 3 (Part 1). Selection of studies on NSAIDs, thermoregulation outcome, and 











































































NA This clinical trial 
investigated if COX 
inhibitors affect core 
temperature rise during 
exercise. The study found 
that combined usage of 
acetaminophen and 
ibuprofen in 15 healthy men 
limited the increase in core 
temperature compared with a 
control during exercise, 
suggesting that 
prostaglandins may have an 
effect on core temperature 
increase during exercise.57  

















Dehydration CKD/AKI Prostaglandins in the kidneys 
are controlled by COX1 and 
COX2 (cyclooxygenase) 
enzymes. During 
dehydration, the kidney 
relies on prostaglandins to 
vasodilate and increase renal 
blood flow; this animal 
model showed that COX2, 
but not COX1, levels 
increase significantly in the 
renal medulla interstitial 
cells along with renal NF-
kappaB-driven reporter. 
COX2 production inhibition, 
such as with NSAIDs, could 
















NA This clinical trial 
investigated NSAIDs effects 
on body temperature and 
melatonin in 75 subjects 
during the day and night. 
They found that NSAIDS did 





Table 3 (Part 2). Selection of studies on NSAIDs, thermoregulation outcome, and 







































































NA This review focused on how 
COX-2 is a rate limiting 
enzyme for PGE2 production 
during febrile thermoregulation, 
which helps raise body core 
temperature as part of the 






















Dehydration NA In a rat model with varied 
hydration levels, the effects of 
different NSAIDs, ibuprofen, 
indomethacin, and meloxicam 
(which is COX-2 selective) 
were examined by looking at 
the kidneys of the mice. All the 
NSAIDs significantly decreased 
AQP2 expression in dehydrated 
rats, and in hydrated rats there 
was less of a change, with no 
significant change with 
meloxicam. There was no 
significant change in 
prostaglandin excretion. In 
addition, ibuprofen prevented 
AQP2 expression increase that 
would normally be observed as 
a reaction to dehydration. 
Overall, the study concluded 
that NSAIDs decrease AQP2 
protein levels, especially during 
modulation during dehydration, 




Table 3 (Part 3). Selection of studies on NSAIDs, thermoregulation outcome, and 













































































Dehydration NA This animal model showed that 
“circulating vasopressin levels 
change in hydrated and 
dehydrated conditions and thus 
control osmotic water 
permeability [(P(f))] of the 
inner medullary collecting duct 
(IMCD). Prostaglandin E2 
(PGE2) antagonizes 



















NA This clinical trial found that 
chronic usage of aspirin at low 
doses will independently limit 
the reflex vasodilation in the 
skin from environmental 
triggers, using 14 individuals 

















NA This review discusses how in 
animal models, salicylate has 
shown to reduce core 
temperature. However, this 
could be due to another cause 




Table 3 (Part 4). Selection of studies on NSAIDs, thermoregulation outcome, and 





























































and skin blood 








Heat stress NA This clinical trial reviews that 
both aspirin and clopidogrel 
increase skin vasodilation and 
the core temperature rate of rise 
in healthy individuals. The 
study had 14 healthy 
individuals rest for 40 min and 
then exercise for up to 2 hours 
in the heat after taking either 
medication. Both medications 
resulted in elevated core 
temperatures during rest in heat 
and “shifted the onset of 
peripheral thermoeffector mech
anisms toward higher body 







Table 4. Selection of studies on acetaminophen, renal outcome, and risk factors 
















The review discusses that there is 
minimal evidence that supports 
chronic usage of acetaminophen 
increasing risk of chronic kidney 
disease and nephrotoxicity. 
Epidemiological studies on healthy 
participants have not shown 
associations between therapeutic 
dosage of acetaminophen and kidney 







ibuprofen on renal 
function in the 
stressed kidney 
AKI Heat stress 
Exercise 
Dehydration 
This clinical trial looked at effects of 
acetaminophen and ibuprofen on renal 
function with participants undergoing 
first a low sodium diet, then 
dehydration, then exercise in the heat 
over 4 days. The combined scenarios 
caused significant decreases in renal 
plasma flow, GFR, and sodium 
excretion. They found that over the 
counter ibuprofen had small but 
statistically significant effects on GFR 
during exercise in a dehydrated and 
low sodium condition, while over the 
counter acetaminophen did not have 








An epidemiological study in Sweden 
found that regular use of 
acetaminophen or aspirin increases 
risk of chronic renal failure by factor 




Acute and Chronic 
Acetaminophen Use 
and Renal Disease: A 
Case-Control Study 




Acute prescription acetaminophen 
use, but not chronic use, was 
associated with renal disease in a 






Table 5 (Part 1). Selection of studies on acetaminophen, thermoregulation, and risk 






























































improves time to 
exhaustion during 












NA This clinical trial investigated the 
effect of acetaminophen on exercise 
capacity through affecting core 
temperature increase during 
exercise. Researchers conducted 
“time-to-exhaustion” trials on a 
cycle ergometer in different hot 
temperatures. After taking 
acetaminophen, the study found that 
participants cycled for significantly 
longer, had lower core, skin, and 
body temperatures, and had lower 
thermal sensation with no 

















Exercise NA In this clinical trial, normal 
therapeutic dosage of 
acetaminophen (20 
mg/kg) significantly reduced core 
temperature, which was monitored 
over a two hour period, in 
participants compared to a 















Exercise NA This clinical study had nine 
participants take either 
acetaminophen or a placebo one 
hour before cycling at a “fixed rate 
of metabolic heat production”. They 
found that there was no difference 
between the acetaminophen and 
placebo in change of core 
temperature, sweat rate, or how the 
participants rated their perceived 
exertion or thermal sensation. They 
concluded that acetaminophen does 
not alter body thermoregulation or 





Table 5 (Part 2). Selection of studies on acetaminophen, thermoregulation, and risk 



























































for altering body 
temperature in 












NA This clinical trial investigated the 
effect of acetaminophen on patients 
experiencing acute stroke, as 
temperature change during stroke 
can have damaging effects to stroke 
outcome. The study concluded that 
giving acetaminophen early on to 
patients (3900 mg/d) with acute 
stroke could cause a small decrease 
in core body temperature. They also 
found that the drug could slightly 
increase likelihood of hypothermia 
<36.5 degrees C or prevent 
hyperthermia >37.5 degrees C, but 






Table 6. Selection of studies on diuretics, renal outcome, thermoregulation, and risk 


































































This clinical trial reviews that 
acetazolamide, a strong carbonic 
anhydrase inhibitor and diuretic, 
is known to decrease exercise 
tolerance under normal and 
hypoxic environments. It 
provides evidence with 7 healthy 
men that reduced ability to 
maintain exercise from diuretic 
usage is from impaired of 
cardiovascular and 
thermoregulation systems, 






















This review discusses how 
diuretics are a common 
medication associated with heat 
related illness. Diuretics can 
cause hypovolemia and 
dehydration, which can lead to 
reduced blood flow to the liver 
and kidneys, reduced medication 
and toxin clearance, and 
electrolyte imbalances, such as 
increased risk of hyperkalemia; 
these can lead to kidney damage. 
They can also cause a reduced 
sensation of thirst.26 








AKI NA Not 
Covere
d 
This retrospective study focused 
on 131 cases of diuretics 
associated AKI, which is 
associated to aging, primary 
diseases and dosage. Using  
diuretics with other drugs, like 
antibiotics and NSAIDs, was 
shown to induce AKI. AKI 
injury from diuretics was mostly 




Table 7 (Part 1). Selection of studies on aminoglycoside antibiotics, analgesic 
opioids, potassium supplements, and urinary antiseptics’ relation to renal and 
thermoregulation outcomes 











































AKI NA This review described 
nephrotoxicity from 
aminoglycoside antibiotics, 
from drug uptake by 
proximal tubular cells into 
lysosomes, which 
can develop into lysosomal 
phospholipidosis and lead 
to cell necrosis 
tubular regeneration, 
peritubular proliferation, 











review of literature 
AKI NA This review stated that there 
is substantial evidence that 
aminoglycoside antibiotics 
cause renal toxicity from 
uptake from the luminal 







What Do We Know 




NA This review concluded that 
evidence shows a link 
between opioid use and 
acute and chronic kidney 
disease.  
They also found that 
nephrotoxicity from opioid 
use seems to be associated 










and accentuate the 
risk of dehydration 
and heat-related 
illness during hot 
weather 
AKI NA This review described how 
reduced renal clearance 
from dehydration causes 
drug toxicity, such as with 
the opioid oxycodone.26 
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Table 7 (Part 2). Selection of studies on aminoglycoside antibiotics, analgesic 
opioids, potassium supplements, and urinary antiseptics’ relation to renal and 
thermoregulation outcomes 












































and accentuate the 
risk of dehydration 
and heat-related 









This review discussed how use 
of analgesic opioids can cause 
sedation and cognitive 
impairment. This can result in 
altered judgment, alertness, and 
sensitivity to heat. Opioids with 
anticholinergic traits can also 










CKD NA This review concluded that 
hyperkalemia from dietary 
supplements may be an issue in 










possible relation to 
acute renal failure 
AKI NA This case study documents an 
18 year old woman with no 
prior kidney history developing 
severe, acute 
methemoglobinemia after 
overdosing on phenazopyridine 
hydrochloride (Pyridium). 
Methylene blue reversed the 
methemoglobinemia, but the 
patient developed hemolytic 
anemia and acute renal failure; 
she ultimately fully recovered. 
The study concludes that renal 
failure should be considered as 
a result of phenazopyridine-
related methemoglobinemia 





Table 8 (Part 1). Selection of studies on renal and thermoregulation outcomes from 












































AKI NA This review showed a lack of research on 
medication combination associated AKI, 
but the most evidence was for the 
combination of NSAIDS and diuretics 





Combined use of 
nonsteroidal anti-
inflammatory drugs 
with diuretics and/or 
renin–angiotensin 
system inhibitors in 
the community 
increases the risk of 
acute kidney injury 
AKI NA In this cohort study, NSAIDs combined 
with two other drugs had a higher increase 
of risk for AKI versus combination with 
one other drug for renin–angiotensin 
inhibitors or diuretics. AKI risk was highest 
for combinations of loop diuretics and 
aldosterone antagonist, in people over 75 
years old, and in people with prior renal 
issues.79 
Izhar et al. 
(2004) 
Effects of COX 
inhibition on blood 
pressure and kidney 
function in ACE 
inhibitor-treated 




Diclofenac (an NSAID) & celecoxib 
increase systolic blood pressure in 
combination with ACE inhibitors but have 







and accentuate the 
risk of dehydration 
and heat-related 







This review discussed how diuretics, 
especially with ACE Inhibitors, ARBs, 
anticholinergics, or psychotropics, have 




















This clinical trial investigated if COX 
inhibitors affect core temperature rise 
during exercise. The study found that 
combined usage of acetaminophen and 
ibuprofen in 15 healthy men limited the 
increase in core temperature compared with 
a control during exercise, suggesting that 
prostaglandins may have an effect on core 









El Salvador Nicaragua 
Sugarcane Corn Construction Sugarcane Brick Plantain 






























































































































aThe left sub-column in each industry represents eGFR values from Round 1 of data collection, which was at the time of baseline after a three day 




Table 10 (Part 1). Participant self-reported medication usage 1 week and 1 year 
prior to baseline by country and industry (n=524) 
Medication Usage,  
N (%) 
Overall 
El Salvador Nicaragua 
Sugarcane Corn Construction Sugarcane Brick Plantain 
 N (%) n (%) n (%) n (%) n (%) n (%) n (%) 
Acetaminophen        
Within the last week 112 (21) 40 (38) 29 (28) 13 (31) 19 (16) 7 (7) 4 (8) 
Within the last year 297 (57) 67 (64) 73 (71) 30 (71) 60 (50) 48 (47) 19 (37) 
Aminoglycoside 
Antibiotics          
Within the last week 5 (1) 1 (1) 3 (3) 0 (0) 0 (0) 0 (0) 1 (2) 
Within the last year 16 (3) 2 (2) 2 (2) 0 (0) 7 (6) 3 (3) 2 (4) 
Analgesic Opioids          
Within the last week 2 (0) 2 (2) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Within the last year 6 (1) 3 (3) 0 (0) 0 (0) 1 (1) 2 (2) 0 (0) 
Diuretics          
Within the last week 7 (1) 0 (0) 0 (0) 0 (0) 0 (0) 6 (6) 1 (2) 
Within the last year 18 (3) 0 (0) 0 (0) 0 (0) 2 (2) 14 (14) 2 (4) 
NSAIDs          
NSAIDs - Ibuprofen          
Within the last week 48 (9) 4 (4) 5 (5) 7 (17) 15 (13) 8 (8) 9 (17) 
Within the last year 154 (29) 9 (9) 25 (24) 18 (43) 45 (38) 38 (37) 19 (37) 
NSAIDs - Dipirona          
Within the last week 3 (1) 1 (1) 0 (0) 0 (0) 1 (1) 1 (1) 0 (0) 
Within the last year 12 (2) 2 (2) 1 (1) 0 (0) 4 (3) 4 (4) 1 (2) 
NSAIDs - Aleve          
Within the last week 1 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 0 (0) 
Within the last year 13 (2) 1 (1) 2 (2) 1 (2) 1 (1) 6 (6) 2 (4) 
NSAIDs - Metamizole          
Within the last week 11 (2) 1 (1) 0 (0) 0 (0) 1 (1) 6 (6) 3 (6) 
Within the last year 50 (10) 3 (3) 6 (6) 1 (2) 3 (3) 27 (26) 10 (19) 
NSAIDs - Meloxicam          
Within the last week 2 (0) 1 (1) 1 (1) 0 (0) 0 (0) 0 (0) 0 (0) 




Table 10 (Part 2). Participant self-reported medication usage 1 week and 1 year 
prior to baseline by country and industry (n=524) 
Medication Usage, N (%) Overall 
El Salvador Nicaragua 
Sugarcane Corn Construction Sugarcane Brick Plantain 
 N (%) n (%) n (%) n (%) n (%) n (%) n (%) 
NSAIDs - Motrin          
Within the last week 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Within the last year 1 (0) 0 (0) 0 (0) 0 (0) 1 (1) 0 (0) 0 (0) 
NSAIDs - Diclofenac          
Within the last week 12 (2) 0 (0) 3 (3) 0 (0) 2 (2) 5 (5) 2 (4) 
Within the last year 87 (17) 2 (2) 11 (11) 7 (17) 22 (18) 31 (30) 14 (27) 
NSAIDs - Ketoprofen          
Within the last week 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Within the last year 7 (1) 0 (0) 0 (0) 0 (0) 3 (3) 3 (3) 1 (2) 
NSAIDs - Other          
Within the last week 1 (0) 0 (0) 0 (0) 0 (0) 1 (1) 0 (0) 0 (0) 
Within the last year 3 (1) 0 (0) 0 (0) 0 (0) 1 (1) 2 (2) 0 (0) 
NSAIDs - Not Specified          
Within the last week 25 (5) 18 (17) 3 (3) 3 (7) 1 (1) 0 (0) 0 (0) 
Within the last year 58 (11) 39 (37) 10 (10) 5 (12) 3 (3) 0 (0) 1 (2) 
Aspirin          
Within the last week 17 (3) 4 (4) 6 (6) 1 (2) 2 (2) 2 (2) 2 (4) 
Within the last year 33 (6) 11 (10) 10 (10) 1 (2) 4 (3) 5 (5) 2 (4) 
Potassium Supplements          
Within the last week 5 (1) 0 (0) 1 (1) 0 (0) 4 (3) 0 (0) 0 (0) 
Within the last year 16 (3) 3 (3) 2 (2) 0 (0) 7 (6) 4 (4) 0 (0) 
Urinary Antiseptics          
Within the last week 8 (2) 0 (0) 0 (0) 0 (0) 2 (2) 5 (5) 0 (0) 





Table 11 (Part 1). Participant self-reported symptom presentation 24 hours and 3 
months prior to baseline by country and industry (n=524) 
Symptoms Exhibited, 
N (%) 
 El Salvador Nicaragua 
Overall Sugarcane Corn Construction Sugarcane Brick Plantain 
 N (%) n (%) n (%) n (%) n (%) n (%) n (%) 
Lower abdominal pain          
Within the last 24 hours 49 (9) 17 (16) 9 (9) 7 (17) 5 (4) 8 (8) 3 (6) 
Within the last 3 months 97 (19) 28 (27) 22 (21) 11 (26) 16 (13) 14 (14) 6 (12) 
Back Pain          
Within the last 24 hours 49 (9) 17 (16) 9 (9) 7 (17) 5 (4) 8 (8) 3 (6) 
Within the last 3 months 315 (60) 71 (68) 64 (62) 26 (62) 56 (47) 69 (67) 29 (56) 
Flank Pain          
Within the last 24 hours 62 (12) 21 (20) 9 (9) 6 (14) 11 (9) 9 (9) 6 (12) 
Within the last 3 months 119 (23) 33 (31) 19 (18) 9 (21) 23 (19) 28 (27) 7 (13) 
Chistata          
Within the last 24 hours 66 (13) 17 (16) 18 (17) 6 (14) 10 (8) 11 (11) 4 (8) 
Within the last 3 months 227 (43) 53 (50) 64 (62) 18 (43) 26 (22) 48 (47) 17 (33) 
Increased Urination Frequency          
Within the last 24 hours 33 (6) 12 (11) 9 (9) 1 (2) 8 (7) 1 (1) 2 (4) 
Within the last 3 months 99 (19) 30 (29) 33 (32) 4 (10) 21 (18) 6 (6) 5 (10) 
Fever or Chills          
Within the last 24 hours 23 (4) 9 (9) 1 (1) 3 (7) 7 (6) 2 (2) 1 (2) 
Within the last 3 months 86 (16) 26 (25) 16 (16) 9 (21) 17 (14) 12 (12) 6 (12) 
Muscle Cramps          
Within the last 24 hours 33 (6) 13 (12) 8 (8) 3 (7) 6 (5) 3 (3) 0 (0) 
Within the last 3 months 130 (25) 36 (34) 28 (27) 9 (21) 15 (13) 31 (30) 11 (21) 
Headache          
Within the last 24 hours 82 (16) 21 (20) 26 (25) 4 (10) 14 (12) 8 (8) 9 (17) 
Within the last 3 months 225 (43) 63 (60) 49 (48) 20 (48) 40 (34) 29 (28) 24 (46) 
Lack of Sweating          
Within the last 24 hours 16 (3) 4 (4) 7 (7) 0 (0) 4 (3) 1 (1) 0 (0) 
Within the last 3 months 37 (7) 10 (10) 11 (11) 3 (7) 4 (3) 7 (7) 2 (4) 
Nausea          
Within the last 24 hours 14 (3) 5 (5) 2 (2) 0 (0) 3 (3) 2 (2) 2 (4) 




Table 11 (Part 2). Participant self-reported symptom presentation 24 hours and 3 
months prior to baseline by country and industry (n=524) 
Symptoms Exhibited, N (%) 
 
Overall 
El Salvador Nicaragua 
Sugarcane Corn Construction Sugarcane Brick Plantain 
 N (%) n (%) n (%) n (%) n (%) n (%) n (%) 
Vomiting          
Within the last 24 hours 7 (1) 3 (3) 1 (1) 0 (0) 3 (3) 0 (0) 0 (0) 
Within the last 3 months 33 (6) 7 (7) 10 (10) 2 (5) 9 (8) 2 (2) 3 (6) 
Palpitations          
Within the last 24 hours 16 (3) 5 (5) 4 (4) 0 (0) 3 (3) 3 (3) 1 (2) 
Within the last 3 months 76 (15) 23 (22) 25 (24) 2 (5) 11 (9) 10 (10) 5 (10) 
Shortness of Breath          
Within the last 24 hours 17 (3) 2 (2) 4 (4) 0 (0) 7 (6) 4 (4) 0 (0) 
Within the last 3 months 59 (11) 11 (10) 14 (14) 1 (2) 15 (13) 15 (15) 3 (6) 
Lightheadedness or Dizziness          
Within the last 24 hours 14 (3) 4 (4) 3 (3) 1 (2) 5 (4) 1 (1) 0 (0) 
Within the last 3 months 60 (11) 13 (12) 23 (22) 4 (10) 9 (8) 8 (8) 3 (6) 
Fainting          
Within the last 24 hours 1 (0) 0 (0) 0 (0) 0 (0) 1 (1) 0 (0) 0 (0) 
Within the last 3 months 11 (2) 2 (2) 3 (3) 0 (0) 4 (3) 1 (1) 1 (2) 
Confusion          
Within the last 24 hours 3 (1) 1 (1) 1 (1) 0 (0) 1 (1) 0 (0) 0 (0) 
Within the last 3 months 11 (2) 3 (3) 2 (2) 1 (2) 4 (3) 1 (1) 0 (0) 
Delirium          
Within the last 24 hours 2 (0) 1 (1) 1 (1) 0 (0) 0 (0) 0 (0) 0 (0) 
Within the last 3 months 5 (1) 2 (2) 1 (1) 0 (0) 1 (1) 1 (1) 0 (0) 
Decreased Urine Quantity          
Within the last 24 hours 15 (3) 4 (4) 3 (3) 2 (5) 4 (3) 2 (2) 0 (0) 
Within the last 3 months 37 (7) 6 (6) 13 (13) 3 (7) 10 (8) 3 (3) 2 (4) 
Dry Mouth          
Within the last 24 hours 44 (8) 14 (13) 5 (5) 0 (0) 13 (11) 9 (9) 3 (6) 




Table 12. Chi-square frequency tests for self-reported medication use and eGFR 
Medication 
Chi-Square Frequency Test, p-valuea 
Short-termb p-value Long-termc p-value 
Acetaminophen 0.16 0.69 0.005 0.95 
NSAIDS 3.06 0.08 0.09 0.76 
aChi-sqaured frequency test for medication usage, binned by usage or no usage, and 
eGFR, binned by >=60 ml/min per 1.73 m2 or <60 ml/min per 1.73 m2. All tests had 
degrees of freedom=1 and n=524. Analgesic opioids, aminoglycoside antibiotics, 
diuretics, aspirin, potassium supplements, and urinary antiseptics sample sizes were 
too small to retrieve accurate results. 
bShort-term considers 1 week usage and round 1 eGFR      
cLong-term considers 1 year usage and mean of round 1 and round 2 eGFR   
ep-value <0.20      
fp-value <0.10      





Table 13. Crude associations between medication usage and eGFR < 60 ml/min per 
1.73 m2 
Medication 
Mean Difference (95% Confidence Interval), p-valuea 
Short Termb p-value Long Termc p-value 
Acetaminophen -0.3 (-2.9 to 2.2) 0.91  1.1 (0.6 to 1.7) 0.64 
Aminoglycoside 
Antibiotics 
    -2.1 (-11.3 to 7.2) 0.77 
Diuretics      1.8 (-8.4 to 11.9) 0.79 
NSAIDS -7.8 (-11.6 to -3.9) 0.02  0.4 (0 to 0.8) 0.87 
Aspirin  0.4 (-10.1 to 11) 0.95 -1.5 (-9.2 to 6.3) 0.76 
Potassium Supplements     -15.2 (-32.8 to 2.5) 0.13 
Urinary Antiseptics      3.6 (-3.8 to 11.1) 0.47 
aMean difference in eGFR measurements between groups separated by self-reported 
usage (usage - no usage), tested by two-sample t tests. Analgesic opioids for both short 
and long term time frames had a sample size of less than 10 and was not able to be run 
by the model. 
bShort term considers 1 week usage and 
round 1 eGFR  
  
  
cLong term cross sectional considers 1 year usage and mean of round 1 and 
round 2 eGFR 
  
dsample size <10, no 
test run 
   
  
ep-value <0.20 
   
  
fp-value <0.10 
   
  





Table 14. Adjusted associations of medication usage and eGFR < 60 ml/min per 1.73 
m2 
Medication 
Odds Ratios (95% Confidence Intervals), p-valuea 
Short Termb p-value Long Termc p-value 
Acetaminophen 0.71 (0.32 - 1.56) 0.39 0.94 (0.48 - 1.84) 0.85 
Diuretics     0.54 (0.06 - 4.99) 0.59 
NSAIDS 1.04 (0.48 - 2.26) 0.92 0.82 (0.42 - 1.58) 0.55 
Aspirin 0.45 (0.05 - 3.77) 0.46 0.86 (0.26 - 2.87) 0.80 
Potassium Supplements     6.27 (1.40 - 27.99)h 0.02 
Urinary Antiseptics     0.41 (0.08 - 2.02) 0.27 
aOdds ratios for self-reported medication usage and eGFR from logistic regressions, 
adjusting for age, country, and job industry. Analgesic opioids and aminoglycoside 
antibiotics for both short and long term timeframes had sample sizes less than 10 and 
were not able to be run by the model. 
bShort term considers 1 week usage and 
round 1 eGFR      
cLong term cross sectional considers 1 year usage and mean of round 1 and 
round 2 eGFR   
dsample size <10, no 
test run      
ep-value <0.20      
fp-value <0.10      




Table 15. Chi-square frequency tests for self-reported symptom presentation and 
eGFR 
Symptom 
Chi-Square Frequency Test, p-valuea 
Short-termb p-value Long-termc p-value 
Lower Abdominal Pain     2.47 0.12 
Back Pain 2.01 0.16 0.22 0.64 
Flank Pain 3.23 0.07 1.04 0.31 
Chistata 0.41 0.52 6.13 0.01 
Frequent Urination     0.75 0.39 
Fever     0.0005 0.98 
Muscle Cramps     0.41 0.52 
Headache 5.96 0.01 1.41 0.23 
Palpitations     6.31 0.01 
Shortness of Breath     0.05 0.82 
Lightheadedness     6.45 0.01 
Dry Mouth     0.70 0.40 
aChi-sqaure frequency test for symptom presentation, binned by presentation or no 
presentation, and eGFR, binned by >=60 ml/min per 1.73 m2 or <60 ml/min per 1.73 
m2. All tests had degrees of freedom=1 and n=524. Sample sizes for lack of sweating, 
nausea, vomiting, fainting, confusion, delirium, and decreased urine quality were too 
small to retrieve accurate results and were not tested. 
bShort-term considers presentation within 24 hours and round 1 
eGFR     
cLong-term considers presentation within 3 months and mean of round 1 and 
round 2 eGFR   
dsample size <5 in 
distribution cells, too 
small to run valid chi 
square      
ep-value <0.20      
fp-value <0.10      




Table 16. Crude associations between symptom presentation and eGFR 
Symptom 




Long Termc p-value 
Lower Abdominal 
Pain -2.2 (-7.2 to 2.8) 0.61 0.9 (-1.1 to 3) 0.77 
Back Pain -3.7 (-5.4 to -1.8) 0.17 -0.4 (-1.3 to 0.5) 0.89 
Flank Pain -8.6 (-14.2 to -2.8) 0.03 -3.5 (-6.6 to -0.4) 0.22 
Chistata 1.8 (-1.6 to 5.3) 0.62 11.2 (10.6 to 11.7) <0.0001 
Frequent Urination -6.4 (-16 to 3.3) 0.21 2.5 (0.2 to 4.9) 0.41 
Fever -13.5 (-24.9 to -1.9) 0.03 0 (-3.3 to 3.2) 0.99 
Muscle Cramps -12.8 (-22.7 to -2.8) 0.05 -2.9 (-5.3 to -0.6) 0.29 
Headache -8.4 (-13.2 to -3.5) 0.04 0.6 (0.1 to 1) 0.81 
Lack of Sweating -10.9 (-24.9 to 3.2) 0.13 -12.2 (-20.9 to -3.5) 0.01 
Nausea -8.8 (-26.5 to 8.9) 0.25 -2.3 (-7.2 to 2.7) 0.59 
Vomiting     -4.5 (-10.8 to 1.6) 0.36 
Palpitations -18.8 (-37.8 to 0) 0.08 -5.3 (-9.8 to 0.8) 0.12 
Shortness of Breath 4.2 (-5.9 to 14.4) 0.55 -1.6 (-5.9 to 2.7) 0.68 
Lightheadedness -8.5 (-24.4 to 7.5) 0.27 -7.3 (-13 to -1.8) 0.05 
Decreased Urine 
Quality -9.4 (-28.5 to 9.7) 0.37 3.6 (-1.4 to 8.6) 0.44 
Dry Mouth -9.5 (-17.5 to -1.3) 0.09 1.3 (-1.1 to -3.9) 0.65 
aMean difference in eGFR measurements between groups separated by self-reported 
symptom presentation (presentation - no presentation), tested by two-sample t tests. 
Fainting, confusion, and delirium for both short and long term time frames had sample 
sizes less than 10 and were not able to be run by the model with accurate results. 
bShort term considers presentation within 24 hours and 
round 1 eGFR     
cLong term considers presentation within 3 months and mean of round 1 and 
round 2 eGFR   
dsample size <10, no 
test run      
ep-value <0.20      
fp-value <0.10      




Table 17. Adjusted association of symptom presentation and eGFR 
Symptom 
Odds Ratios (95% Confidence Intervals), p-valuea 




Pain 0.40 (0.13 - 1.29) 0.13 0.35 (0.13 - 0.99) 0.05 
Back Pain 1.14 (1.09 - 1.19) 0.63 1.01 (0.52 - 1.99) 0.97 
Flank Pain 1.37 (0.58 - 3.20) 0.47 1.08 (0.52 - 2.28) 0.83 
Chistata 0.53 (0.19 - 1.49) 0.23 0.37 (0.18 - 0.77) 0.008 
Frequent Urination 1.72 (0.55 - 5.38) 0.36 0.48 (0.19 - 1.24) 0.13 
Fever 2.55 (0.75 - 8.72) 0.14 0.92 (0.38 - 2.26) 0.86 
Muscle Cramps 1.99 (0.71 - 5.60) 0.19 0.85 (0.41 - 1.76) 0.66 
Headache 1.38 (0.64 - 2.95) 0.41 1.16 (0.60 - 2.25) 0.67 
Lack of Sweating 2.24 (0.42 - 11.91) 0.34 2.03 (0.75 - 5.45) 0.16 
Nausea 2.24 (0.52 - 9.64) 0.28 0.37 (0.10 - 1.38) 0.14 
Vomiting     1.09 (0.27 - 4.35) 0.90 
Palpitations 3.06 (0.84 - 11.08) 0.09 1.40 (0.63 - 3.13) 0.41 
Shortness of Breath     0.86 (0.32 - 2.35) 0.77 
Lightheadedness 1.54 (0.28 - 8.40) 0.62 1.95 (0.84 - 4.51) 0.12 
Decreased Urine 
Quality 1.31 (0.23 - 7.53) 0.76 0.50 (0.10 - 2.49) 0.40 
Dry Mouth 1.55 (0.60 - 4.04) 0.37 0.56 (0.22 - 1.40) 0.21 
aOdds ratios for self-reported symptom presentation and eGFR, adjusting for age, 
country, and job industry. Fainting, confusion, and delirium for both short and long 
term time frames had sample sizes less than 10 and were not able to be run by the 
model with accurate results. 
bShort term considers presentation within 24 hours and 
round 1 eGFR     
cLong term considers presentation within 3 months and mean of round 1 and 
round 2 eGFR   
dsample size <10, no 
test run      
ep-value <0.20      
fp-value <0.10      
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